{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T07:45:44Z","timestamp":1785915944838,"version":"3.56.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021802","name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021802","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014039","name":"US Department of Defense Prostate Cancer Research Program","doi-asserted-by":"publisher","award":["PC200267"],"award-info":[{"award-number":["PC200267"]}],"id":[{"id":"10.13039\/100014039","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020424","name":"Weill Cornell Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020424","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016936","name":"Loxo Oncology Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016936","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Methods"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.crmeth.2026.101339","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T14:05:06Z","timestamp":1778767506000},"page":"101339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tumor immune microenvironment reconstitution in patient-derived organoids enables therapy modeling for NSCLC"],"prefix":"10.1016","volume":"6","author":[{"given":"Enrique","family":"Podaza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Hsuan","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majd","family":"Al Assaad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Markowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Victoria","family":"Revuelta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Irizarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiranmayi","family":"Ravichandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ackermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyothi","family":"Manohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Duren-Lubanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sigouros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Moyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavneet","family":"Bhinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murtaza","family":"Malbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Boehnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Miguel","family":"Mosquera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sboner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Gokozan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser","family":"Altorki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Elemento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9359-5856","authenticated-orcid":false,"given":"M. Laura","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.crmeth.2026.101339_bib1","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","article-title":"Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US","volume":"7","author":"Ganti","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.crmeth.2026.101339_bib2","doi-asserted-by":"crossref","first-page":"iii27","DOI":"10.1093\/annonc\/mdu199","article-title":"Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Reck","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.crmeth.2026.101339_bib3","first-page":"S389","article-title":"Treatment of non-small cell lung cancer (NSCLC)","volume":"5","author":"Zarogoulidis","year":"2013","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.crmeth.2026.101339_bib4","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3390\/cells13211785","article-title":"Prognostic indicators for precision treatment of non-small cell lung carcinoma","volume":"13","author":"Ghosh","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.crmeth.2026.101339_bib5","first-page":"721","article-title":"Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity","volume":"4","author":"Pilotto","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.crmeth.2026.101339_bib6","article-title":"Advancing non-small cell lung cancer treatment: the power of combination immunotherapies","volume":"15","author":"Wu","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.crmeth.2026.101339_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/1758834017745012","article-title":"Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)","volume":"10","author":"Moya-Horno","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.crmeth.2026.101339_bib8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.crmeth.2026.101339_bib9","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1586\/17512433.2015.1055252","article-title":"Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer","volume":"8","author":"Santarpia","year":"2015","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.crmeth.2026.101339_bib10","doi-asserted-by":"crossref","first-page":"15056","DOI":"10.3390\/ijms232315056","article-title":"Non-small cell lung cancer targeted therapy: drugs and mechanisms of drug resistance","volume":"23","author":"Wu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.crmeth.2026.101339_bib11","article-title":"Therapeutic implications of tumor microenvironment in lung cancer: focus on immune checkpoint blockade","volume":"12","author":"Genova","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.crmeth.2026.101339_bib12","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/nm.3388","article-title":"The quest to overcome resistance to EGFR-targeted therapies in cancer","volume":"19","author":"Chong","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.crmeth.2026.101339_bib13","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1158\/1078-0432.CCR-22-0992","article-title":"PD-1T TILs as a predictive biomarker for clinical benefit to PD-1 blockade in patients with advanced NSCLC","volume":"28","author":"Hummelink","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.crmeth.2026.101339_bib14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2022.4933","article-title":"Association of machine learning-based assessment of tumor-infiltrating lymphocytes on standard histologic images with outcomes of immunotherapy in patients with NSCLC","volume":"9","author":"Rakaee","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.crmeth.2026.101339_bib15","article-title":"The role of tumor-associated macrophages in lung cancer","volume":"16","author":"Zhu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.crmeth.2026.101339_bib16","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1158\/0008-5472.CAN-20-0069","article-title":"Spatial density and distribution of tumor-associated macrophages predict survival in non-small cell lung carcinoma","volume":"80","author":"Zheng","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.crmeth.2026.101339_bib17","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1158\/2159-8290.CD-16-1154","article-title":"Personalized in vitro and in vivo cancer models to guide precision medicine","volume":"7","author":"Pauli","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.crmeth.2026.101339_bib18","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","article-title":"Organoid profiling identifies common responders to chemotherapy in pancreatic cancer","volume":"8","author":"Tiriac","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.crmeth.2026.101339_bib19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.stem.2019.10.010","article-title":"Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer","volume":"26","author":"Yao","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.crmeth.2026.101339_bib20","doi-asserted-by":"crossref","first-page":"eaay2574","DOI":"10.1126\/scitranslmed.aay2574","article-title":"Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients","volume":"11","author":"Ooft","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.crmeth.2026.101339_bib21","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1126\/science.aao2774","article-title":"Patient-derived organoids model treatment response of metastatic gastrointestinal cancers","volume":"359","author":"Vlachogiannis","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.crmeth.2026.101339_bib22","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.1038\/s41596-021-00494-5","article-title":"Author correction: establishment of patient-derived cancer organoids for drug-screening applications","volume":"16","author":"Driehuis","year":"2021","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.crmeth.2026.101339_bib23","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","article-title":"Organoid modeling of the tumor immune microenvironment","volume":"175","author":"Neal","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.crmeth.2026.101339_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-17921-6","article-title":"Application of immune enhanced organoids in modeling personalized Merkel cell carcinoma research","volume":"12","author":"Forsythe","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.crmeth.2026.101339_bib25","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.copbio.2020.05.002","article-title":"Organoid technology and applications in cancer immunotherapy and precision medicine","volume":"65","author":"Homicsko","year":"2020","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.crmeth.2026.101339_bib26","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","article-title":"Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids","volume":"174","author":"Dijkstra","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.crmeth.2026.101339_bib27","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4161\/hv.26593","article-title":"Clinical validation of IFNgamma\/IL-10 and IFNgamma\/IL-2 FluoroSpot assays for the detection of Tr1 T cells and influenza vaccine monitoring in humans","volume":"10","author":"Chauvat","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.crmeth.2026.101339_bib28","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2159-8290.CD-14-1236","article-title":"Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities","volume":"5","author":"Skoulidis","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.crmeth.2026.101339_bib29","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.21037\/tlcr-20-1241","article-title":"A narrative review of tumor-associated macrophages in lung cancer: regulation of macrophage polarization and therapeutic implications","volume":"10","author":"Sedighzadeh","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.crmeth.2026.101339_bib30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","article-title":"A living biobank of breast cancer organoids captures disease heterogeneity","volume":"172","author":"Sachs","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.crmeth.2026.101339_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.641980","article-title":"Patient-derived cancer organoids as predictors of treatment response","volume":"11","author":"Verduin","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.crmeth.2026.101339_bib32","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1158\/1078-0432.CCR-20-5026","article-title":"Modeling clinical responses to targeted therapies by patient-derived organoids of advanced lung adenocarcinoma","volume":"27","author":"Kim","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.crmeth.2026.101339_bib33","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12916-021-02006-4","article-title":"Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors","volume":"19","author":"Wang","year":"2021","journal-title":"BMC Med."},{"key":"10.1016\/j.crmeth.2026.101339_bib34","doi-asserted-by":"crossref","first-page":"e004440","DOI":"10.1136\/jitc-2021-004440","article-title":"Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer","volume":"10","author":"Lopez de Rodas","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.crmeth.2026.101339_bib35","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/01.cji.0000158855.92792.7a","article-title":"Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression","volume":"28","author":"Huang","year":"2005","journal-title":"J. Immunother."},{"key":"10.1016\/j.crmeth.2026.101339_bib36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2004-06-2482","article-title":"Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy","volume":"105","author":"Powell","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.crmeth.2026.101339_bib37","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.crmeth.2026.101339_bib38","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/CJI.0b013e31818403d5","article-title":"Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy","volume":"31","author":"Tran","year":"2008","journal-title":"J. Immunother."},{"key":"10.1016\/j.crmeth.2026.101339_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030852","article-title":"Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization","volume":"7","author":"Baitsch","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.crmeth.2026.101339_bib40","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.crmeth.2026.101339_bib41","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1053\/j.seminoncol.2015.05.002","article-title":"Combined immune checkpoint blockade","volume":"42","author":"Drake","year":"2015","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.crmeth.2026.101339_bib42","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/icb.2015.12","article-title":"Checkpoint inhibitors for cancer immunotherapy: multiple checkpoints on the long road towards cancer immunotherapy","volume":"93","author":"Phan","year":"2015","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.crmeth.2026.101339_bib43","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1873607","article-title":"Addition of anti-TIM3 or anti-TIGIT antibodies to anti-PD1 blockade augments human T cell adoptive cell transfer","volume":"10","author":"Martinez","year":"2021","journal-title":"OncoImmunology"},{"key":"10.1016\/j.crmeth.2026.101339_bib44","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.2012.44.5353","article-title":"ALK in lung cancer: past, present, and future","volume":"31","author":"Shaw","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.crmeth.2026.101339_bib45","doi-asserted-by":"crossref","first-page":"e002917","DOI":"10.1136\/jitc-2021-002917","article-title":"Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer","volume":"9","author":"Zhu","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.crmeth.2026.101339_bib46","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41401-020-00500-8","article-title":"Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity","volume":"41","author":"Sun","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.crmeth.2026.101339_bib47","doi-asserted-by":"crossref","first-page":"a031849","DOI":"10.1101\/cshperspect.a031849","article-title":"Kras and tumor immunity: friend or foe?","volume":"8","author":"Cullis","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.crmeth.2026.101339_bib48","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1038\/s41467-020-19288-6","article-title":"Immune modulatory effects of oncogenic KRAS in cancer","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.crmeth.2026.101339_bib49","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/sj.bjc.6602227","article-title":"Interleukin-8\/CXCL8 is a growth factor for human lung cancer cells","volume":"91","author":"Zhu","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.crmeth.2026.101339_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2023.156133","article-title":"Interleukin 8 in plasma is an efficacy marker for advanced non-small cell lung cancer treated with hypofractionated radiotherapy and PD-1 blockade","volume":"163","author":"Kang","year":"2023","journal-title":"Cytokine"},{"key":"10.1016\/j.crmeth.2026.101339_bib51","article-title":"CD8(+) T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy","volume":"4","author":"Huseni","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.crmeth.2026.101339_bib52","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cyto.2006.01.006","article-title":"Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation","volume":"33","author":"Yan","year":"2006","journal-title":"Cytokine"},{"key":"10.1016\/j.crmeth.2026.101339_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.crmeth.2026.101339_bib54","doi-asserted-by":"crossref","first-page":"7493","DOI":"10.3390\/ijms24087493","article-title":"Tumor-associated macrophage subsets: shaping polarization and targeting","volume":"24","author":"Zhang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.crmeth.2026.101339_bib55","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1164\/rccm.200704-641OC","article-title":"TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer","volume":"177","author":"Ho","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.crmeth.2026.101339_bib56","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.82998","article-title":"The role of macrophages in non-small cell lung cancer and advancements in 3D co-cultures","volume":"12","author":"Balazova","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.crmeth.2026.101339_bib57","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.62347\/BQFH7352","article-title":"In vitro co-culture models for studying organoids-macrophages interaction: the golden technology of cancer immunotherapy","volume":"14","author":"Liu","year":"2024","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.crmeth.2026.101339_bib58","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13046-023-02756-4","article-title":"Macrophage-organoid co-culture model for identifying treatment strategies against macrophage-related gemcitabine resistance","volume":"42","author":"Jiang","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.crmeth.2026.101339_bib59","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/CJI.0b013e31824e801f","article-title":"Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment","volume":"35","author":"Jin","year":"2012","journal-title":"J. Immunother."},{"key":"10.1016\/j.crmeth.2026.101339_bib60","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/cncy.21647","article-title":"An emerging role for cytopathology in precision oncology","volume":"124","author":"Pauli","year":"2016","journal-title":"Cancer Cytopathol."},{"key":"10.1016\/j.crmeth.2026.101339_bib61","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.21873\/anticanres.11486","article-title":"On-site cytology for development of patient-derived three-dimensional organoid cultures: a pilot study","volume":"37","author":"Sailer","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.crmeth.2026.101339_bib62","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.crmeth.2026.101339_bib63","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1158\/2326-6066.CIR-19-0401","article-title":"pVACtools: a computational toolkit to identify and visualize cancer neoantigens","volume":"8","author":"Hundal","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.crmeth.2026.101339_bib64","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.proghi.2006.09.001","article-title":"Heat-induced antigen retrieval: mechanisms and application to histochemistry","volume":"41","author":"Yamashita","year":"2007","journal-title":"Prog. Histochem. Cytochem."}],"container-title":["Cell Reports Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667237526000391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667237526000391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:56:41Z","timestamp":1785913001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667237526000391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2667237526000391"],"URL":"https:\/\/doi.org\/10.1016\/j.crmeth.2026.101339","relation":{},"ISSN":["2667-2375"],"issn-type":[{"value":"2667-2375","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor immune microenvironment reconstitution in patient-derived organoids enables therapy modeling for NSCLC","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crmeth.2026.101339","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101339"}}